Madeline Jones Ryan, DO
Endocrinology, Diabetes & Metabolism · Lincoln, NENPI 1740677608
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,565 of the $3,564 with a category attached, or 72.0%. It is spread thinly across 32 manufacturers, the largest accounting for just 18.4%.
Across 173 payments — averaging $20.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$656
- Lilly USA, LLC$536
- Chiesi USA, Inc.$316
- Novo Nordisk$299
- Ascensia Diabetes Care US Inc.$242
- AstraZeneca$241
- plus $1K from 26 others
Across 40 payments — averaging $6963.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$279K
What the payments were for
- Speaking & faculty fees$95627%
- Food & beverage$2,56572%
- Education$441%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 1 | $656 |
| Lilly USA, LLC | 43 | $536 |
| Chiesi USA, Inc. | 2 | $316 |
| Novo Nordisk | 22 | $299 |
| Ascensia Diabetes Care US Inc. | 18 | $242 |
| AstraZeneca(2 entities) | 11 | $241 |
| Medtronic | 7 | $136 |
| Amgen(2 entities) | 8 | $132 |
| Zealand Pharma US, Inc. | 7 | $109 |
| Sanofi-aventis U.S. LLC | 7 | $106 |
| Mannkind Corporation | 6 | $102 |
| Corcept Therapeutics | 4 | $87 |
| Tandem Diabetes Care, Inc. | 5 | $80 |
| Antares Pharma, Inc. | 3 | $60 |
| Amneal Pharmaceuticals LLC | 3 | $43 |
| Boehringer Ingelheim | 3 | $43 |
| Amryt Pharma Holdings Ltd | 3 | $42 |
| Recordati_rare_diseases_inc. | 2 | $39 |
| Ultragenyx Pharmaceutical Inc. | 2 | $37 |
| Halozyme Inc | 2 | $34 |
| AbbVie | 2 | $32 |
| Dexcom, Inc. | 2 | $32 |
| Eisai Inc. | 1 | $20 |
| Abbott | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| BETA Bionics, Inc. | 1 | $16 |
| Cequr Corporation | 1 | $15 |
| IBSA Pharma Inc. | 1 | $15 |
| Radius Health, Inc. | 1 | $14 |
| Ipsen Biopharmaceuticals, Inc | 1 | $14 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,564 in reported general payments places this provider in the 60th percentile of 43 endocrinology, diabetes & metabolism providers in Nebraska.
See all endocrinology, diabetes & metabolism providers in Nebraska →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 122 | $153,720 |
| OzempicSemaglutide | 70 | $85,058 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $46,778 |
| TrulicityDulaglutide | 44 | $44,995 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 48 | $34,152 |
| JardianceEmpagliflozin | 21 | $33,074 |
| Tresiba Flextouch U-100Insulin Degludec | 46 | $28,528 |
| Tresiba Flextouch U-200Insulin Degludec | 27 | $23,616 |
| FarxigaDapagliflozin Propanediol | 20 | $22,060 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 14 | $12,362 |
| FiaspInsulin Aspart (Niacinamide) | 11 | $11,093 |
| V-Go 30Sub-Q Insulin Device, 30 Unit | 11 | $7,655 |
| Novolog FlexpenInsulin Aspart | 29 | $7,499 |
| SynthroidLevothyroxine Sodium | 80 | $6,448 |
| V-Go 40Sub-Q Insulin Device, 40 Unit | 12 | $6,386 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $536 | $198,715166 claims |
| Novo NordiskOzempic, Fiasp | $299 | $96,15281 claims |
| Boehringer IngelheimJardiance | $43 | $33,07421 claims |
| AstraZenecaFarxiga | $241 | $22,06020 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $106 | $12,36214 claims |
| AbbVieSynthroid | $32 | $6,44880 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $43 | $1,691220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 43 endocrinology, diabetes & metabolism providers in Nebraska.
Other endocrinology, diabetes & metabolism in Lincoln
- Shannon WakeleyLincoln$78K
- Kara Meinke BaehrLincoln$1K
- Prathima JastiLincoln$1K
- Jalal NafachLincoln$110
- Marium IlahiOmaha$170K
- Cyrus DesouzaOmaha$86K
- Timothy WahlOmaha$41K
- Leslie EilandOmaha$17K
- Anupam KotwalOmaha$17K
- John GallagherOmaha$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.